Intrinsiqq
Cocrystal Pharma Inc. logo

Cocrystal Pharma Inc. Quality Score

COCP

Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-1.2x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-2.0x

Negative FCF, no valuation support

Revenue Growth
0/100
-60.2%

Below 2%, essentially flat

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
12331.5%

Heavy dilution above 5%

Margin Trend
0/100
-445.4pp

Contracted >2pp, margin pressure

Capital Structure
100/100
-$4M

Net cash position, no leverage concern

2011
$416333
$4.00M
2019
$7.00M
$817000
2020
$33.0M
$596000
TTM
$5.00M
$1.00M
CashDebt
Return on Capital
0/100
-184.7%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Cocrystal Pharma (COCP) quality: score, margins and returns

Cocrystal Pharma (COCP) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100 and -184.7% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Cocrystal Pharma (COCP) a high-quality business?+

Cocrystal Pharma scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -184.7% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Cocrystal Pharma's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from COCP's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Cocrystal Pharma scores well and where it falls behind.

What is Cocrystal Pharma's return on invested capital (ROIC)?+

Cocrystal Pharma earns about -184.7% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to COCP's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 16 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 16 Nov 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with COCP

CompareIntrinsic value
ORMPOramed Pharmaceuticals Inc.
$3.57-3.25%35
SGMTSagimet Biosciences Inc.
$9.12-5.20%10
DNTHDianthus Therapeutics Inc.
$84.55-0.33%10
CYCNCyclerion Therapeutics Inc.
$35.45+6.55%40
MCRBSeres Therapeutics, Inc.
$1.24-6.77%0
DCOYDecoy Therapeutics Inc.
$0.83-4.67%20
ELTXElicio Therapeutics Inc.
$1.45-3.33%25
SCPXScorpius Holdings Inc.
$0.00+0.00%10

Spot a number that looks wrong? Check it in COCP's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing COCP

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.